With a highly automated approach, Creative Bioarray provides highly cost-efficient S9 stability assay as one of our in vitro metabolism services and delivers consistent and high quality data.
Drug detoxification and drug metabolism are mostly carried out in the liver. Following oral administration, drugs are absorbed and transported to the liver to be metabolized primarily in this organ. About three-quarters of the drugs cleared via metabolism are metabolized by hepatic cytochrome P450 (CYP)-mediated metabolism1. Hepatic in vitro metabolism studies using hepatocytes, 9000g supernatant (S9), and microsomal fractions can give out valuable preliminary information on the in vitro metabolism of xenobiotics and shed light on the in vivo metabolism process of a candidate drug by the liver.
Compared to Hepatocytes which contain the full range of hepatic drug metabolizing enzymes and serve as the gold standard for metabolism studies, the S9 fraction is not only easier to handle but also sustains the major part of both phase I and phase II drug metabolizing enzymes, making it one of the perfect alternatives for in vitro drug metabolism studies.
Creative Bioarray is staffed with a group of well-experienced experts in drug metabolism and is able to provide customized S9 stability assays to assess the metabolic stability of your candidate drugs (microsomal stability assay is also available upon request).
This assay is typically carried out in mouse, rat, and human S9 fraction or microsomes (tests in S9 or microsomes from other species or hepatocytes are available upon request). Test compounds are incubated with S9 fraction supplemented with co-factors at 37°C. 4 sampling time-points (0, 15, 30, and 60 minutes) are set up in duplicates. At each time-point, the reactions are terminated and samples are centrifuged, filtered and subjected to LC-MS/MS analysis to evaluate the parent compound concentration. This service also includes incubation of 1-2 control drugs and a control reaction without co-factors.
Test system available
Different species of S9 fractions or microsomes can be used in this assay to enable a better understanding of interspecies differences in drug metabolism. Those species include human, mouse, rat, rabbit, dog, monkey, guinea pig, minipig, and other species.
Creative Bioarray’s S9 stability assay can be further extended to metabolite profiling and give out more information about the metabolism of your compound. Liver microsomal stability assay and hepatocyte stability assay are also available at Creative Bioarray. Liver S9 fraction (Cat. CSC-C4093X) as a product can be used in genotoxicity tests such as Ames test as a metabolic activator. To find out more about our services and products, please feel free to leave a message below, or contact us at firstname.lastname@example.org or 1-631-626-9181.
||Wienkers, Larry C., and Timothy G. Heath. "Predicting in vivo drug interactions from in vitro drug discovery data." Nature reviews Drug discovery 4.10 (2005): 825-833.